- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01528878
Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases
A Dose-finding, Safety and Preliminary Efficacy Study of Stereotactic Radiosurgery for Hepato-cellular Carcinoma and Metastatic Disease to the Liver.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
-
Greenville, North Carolina, United States, 27858
- East Carolina Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hepatocellular carcinoma (as defined by biopsy or alpha-fetoprotein (AFP) greater than 1000ng/dL with appropriate imaging) or liver metastases from colorectal cancer or other tumor (as defined by biopsy or elevated Carcinoembryonic antigen (CEA) or a positive positron emission tomography (PET) scan in conjunction with a mass on CT or MRI in a patient with previously resected cancer). Patients with at least one measurable liver lesion and no more than 3 are eligible if they meet all other eligibility criteria including the dose constraints on the composite plan.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Patients are not candidates for definitive surgical resection because of tumor location, hepatic function, or other medical or personal reasons.
- Patients with HCC who are being considered for liver transplant may be entered as a bridge to transplant if it is considered by the transplant team that an ablative therapy would be of value while awaiting transplant.
- If cirrhosis is present, patients will have Child-Pugh score of A or B (see Appendix A in the Master Protocol).
- Patients will have tumors not optimally treated with radio-frequency ablation by interventional radiology, or by GI/transplant surgery. This could be for reasons of size, tumor location, or other reasons.
- Ability to place fiducial markers in the vicinity of the tumor to allow for radiographic tracking of respiratory motion and tumor localization. Fiducial placement will generally be done by interventional radiology.
- Estimates of hepatic tolerance must meet the criteria as defined in Section III. This eligibility will not be able to made definitively until the patient has agreed to participate. in the study and the appropriate scan analyses and dosimetry have been performed. No more than one decrement in dose from the planned dose level will be allowed for an individual patient because of exceeding the maximal liver doses before the patient is declared ineligible for study.
Adequate bone marrow and renal function as assessed by the following:
- Absolute neutrophil count (ANC) > 1000/mm3
- Platelet count > 80,000/mm3
- Creatinine < 2.0 mg/dL OR Creatinine clearance > 45 mL/min based on Cockcroft-Gault formula).
- Patients with extra hepatic metastatic disease are eligible if it is the opinion of the treating physician that local therapy to the liver may produce worthwhile clinical benefits
- Patient is able to understand fully the potential risks and benefits of this approach and signs an appropriate informed consent.
- Male and female of >18 years of age. Male or female patients capable of reproduction must agree to use medically acceptable methods of contraception, such as an intrauterine device, diaphragm, with spermicide, condom with spermicide or abstinence. Inclusion of females of childbearing potential requires a negative pregnancy test within 14 days prior to study initiation.
Exclusion Criteria:
- Child-Pugh Class C cirrhosis
- Patients with clinically apparent central nervous system (CNS) disease.
- Medical or psychiatric illness that would not allow the patient to tolerate the proposed treatment including inability to lie flat for an extended period of time, severe claustrophobia or other reasons.
- Uncontrolled or significant cardiovascular disease including: myocardial infarction within 6 months, uncontrolled angina within 6 months, Class III-IV New York Heart Association (NYHA) congestive heart failure, grade 3 cardiac valve dysfunction
- Evidence of decompensated liver disease as evidenced by: clinically significant ascites refractory to diuretic therapy) evidence of hepatic encephalopathy, coagulopathy not corrected by conservative measures.
- A history of CTCAE Grade 3 bleeding esophageal or gastric varices within the past 2 months. Prior variceal bleed permitted if patient has undergone banding or sclerotherapy and there has been no evidence of bleeding for 2 months. Patients at risk for varices (based on the following: known history of esophageal or gastric varices; evidence of hepatic cirrhosis and/or portal hypertension including biopsy-proven cirrhosis, hypersplenism, or radiographic findings of varices) will be screened for esophageal varices. If varices are identified that require intervention (banding), patient will not be eligible until varices adequately treated.
- Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.
- Uncontrolled intercurrent illness.
- Inability to comply with study and/or follow-up procedures.
- A patient with Child-Pugh Class A will not be eligible for study if the liver dose constraint described in Section 3.2 cannot be met after two decrements in dose per fraction as described above.
- A patient with Child-Pugh Class B will not be eligible for study if the liver dose constraint described in Section 3.2 cannot be met after two decrements in dose per fraction as described above.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Good liver function.
Patients with good liver function as defined by no more than Child-Pugh Class A.
|
Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used. The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy.
Other Names:
|
Experimental: Compromised liver function.
Patients with compromised liver function as defined by patients with Child-Pugh Class B.
|
Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used. The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerability of Stereotactic Body Radiotherapy (SBRT) Based on Number of Cumulative Acute Toxicities Occurring Within 90 Days of Treatment and Related to SBRT.
Time Frame: 90 days
|
To determine a tolerable dose, cumulative acute toxicity was collected (defined as toxicity occurring within 90 days of treatment initiation).
Adverse events were graded by the Common Terminology Criteria for Adverse Events version 3.0.
Tolerability was based on hepatic toxicity.
A grading (severity) scale is provided for each adverse event (AE) term.
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL).
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.
Grade 4 Life-threatening consequences; urgent intervention indicated.
Grade 5 Death related to AE.
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local Tumor Control to Doses of Radiation in Patients With Liver Cancer or Metastases to the Liver
Time Frame: 12.7 months
|
1 year local control defined as percentage of patients with freedom from local progression at a median follow-up time of 12.7 months.
Progressive disease is defined as increase by >= 50% of product of the two perpendicular diameters of an irradiated lesion.
|
12.7 months
|
Percentage of Local Response to Doses of Radiation in Patients With Liver Cancer or Metastases to the Liver
Time Frame: 6 months
|
Complete response (CR) is defined as disappearance of the target lesion, partial response (PR) as regression of measureable disease, progressive disease (PD) as increase by >= 50% in product of the two perpendicular diameters of an irradiated lesion, and stable disease (SD) as all others not meeting criteria for CR, PR, or PD.
|
6 months
|
Overall Survival of Patients With Liver Cancer or Metastases to the Liver
Time Frame: 1 year
|
Overall survival is defined as percentage of patients remaining alive from start of study treatment to 1 year.
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Joel Tepper, MD, University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Liver Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Neoplastic Processes
- Colorectal Neoplasms
- Neoplasms
- Neoplasm Metastasis
- Liver Neoplasms
- Colonic Neoplasms
Other Study ID Numbers
- LCCC 0809
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Neoplasms
-
Ethicon, Inc.Terminated
-
Ethicon, Inc.RecruitingLiver Cancer | Cancer of the Liver | Neoplasms, LiverUnited Kingdom, United States, Netherlands, Singapore, France, Germany, China, Korea, Republic of
-
Ewha Womans University Mokdong HospitalSeoul St. Mary's Hospital; Pusan National University Hospital; Chonnam National... and other collaboratorsUnknown
-
China Medical University HospitalActive, not recruitingLiver Transplant, Liver Cancer, ImmunosuppressantTaiwan
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedLiver Tumor | Evidence of Liver TransplantationChina
-
Slawa CwajnaNova Scotia Health AuthorityWithdrawnPrimary Liver Cancer | Metastatic Liver CancerCanada
-
Medical University of WarsawJagiellonian University; Medical University of Lublin; Medical University of... and other collaboratorsRecruiting
-
Beijing Immunochina Medical Science & Technology...Recruiting
-
Gustave Roussy, Cancer Campus, Grand ParisRecruiting
-
Masa BosnjakUniversity of Ljubljana; Institute of Oncology LjubljanaCompleted
Clinical Trials on Stereotactic Radiosurgery using the CyberKnife System.
-
Accuray IncorporatedUniversity of PittsburghUnknownNon-small Cell Lung CancerUnited States, China
-
Accuray IncorporatedCompletedProstatic Neoplasms | Prostate Cancer | Prostate Neoplasms | Cancer of the Prostate | Prostatic CancerUnited States
-
Accuray IncorporatedCompletedProstatic Neoplasms | Prostate Cancer | Prostate Neoplasms | Cancer of the Prostate | Prostatic CancerUnited States
-
Swedish Medical CenterRecruitingProstatic Neoplasms | Prostate Cancer | Prostate Neoplasms | Cancer of the Prostate | Prostatic CancerUnited States
-
Stanford UniversityCompleted
-
Peking University Third HospitalUnknownSpinal NeoplasmsChina
-
Boston Medical CenterUnited States Department of DefenseCompletedHead and Neck CancerUnited States
-
Beth Israel Deaconess Medical CenterCompleted
-
Steven BurtonActive, not recruiting
-
Georgetown UniversityRecruitingProstate Cancer | Localized Malignant NeoplasmUnited States